In second- or later-line setting, combination cut risk of disease progression or death by ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDTCompany ParticipantsBassil Dahiyat - Co-Founder, ...

Epcoritamab plus R-DHAX/C achieved 79% ORR and 69% CR, with median 1.4 months to response and early activity evident by the first week-6 assessment. Over half of patients reached ASCT after ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

He is the lead principal investigator of the ALLEGORY study and the lead author and he has also presented the results last Friday at SLEuro. Today, Dr. Richard Furie will take us again through the ...

Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States Division of Infectious Disease and Vaccinology, ...

过去两年，细胞治疗赛道正经历一场隐秘而猛烈的底层重构。礼来收购Orna、艾伯维拿下Capstan、BMS也躬身入局……跨国巨头们超60亿美元的密集扫货，释放出一个极其明确的信号：In vivo CAR-T已处于产业化爆发的前夕。 传统Ex vivo CAR-T动辄数十万美元的定价与繁杂的制备周期，使其深陷个性化定制的商业泥沼，而In vivo CAR-T正以颠覆者的姿态，将细胞疗法拉回现代制药的规 ...

The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with ...

Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

Healsan技术加持，让科研和SCI论文成为临床工作的副产品。CAR-T细胞疗法在血液肿瘤领域及自身免疫性疾病方面都已改变治疗格局，但在实体瘤中始终未能取得类似突破。其核心瓶颈并不完全来自肿瘤微环境或T细胞衰竭，而是一个更基础的问题--缺乏真正具有 ...

Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs' or the 'Company,' Stock Code: 9887.HK) announced on March 6, 2026 that the ...

This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal ...